Quarterly ResultMay 4, 2026, 04:38 PM
Cryoport Q1 Revenue +16% to $47.8M; Raises Full-Year Guidance
AI Summary
Cryoport reported strong first-quarter 2026 financial results, with total revenue increasing 16% year-over-year to $47.8 million. This growth was driven by a 26% rise in commercial cell and gene therapy revenue and robust performance across both Life Sciences Services (+18%) and Products (+15%) segments. The company also raised its full-year revenue guidance to $192 million - $196 million, reflecting continued momentum and strategic expansion plans, including new global supply chain centers. Adjusted EBITDA from continuing operations showed a significant improvement, narrowing the loss to $0.6 million.
Key Highlights
- Total revenue grew 16% year-over-year to $47.8 million.
- Commercial cell and gene therapy revenue increased 26% year-over-year to $9.1 million.
- Life Sciences Services revenue rose 18% year-over-year to $26.9 million.
- Life Sciences Products revenue increased 15% year-over-year to $20.9 million.
- Adjusted EBITDA from continuing operations improved to negative $0.6 million from negative $2.8 million.
- Supported a record 766 global clinical trials and 21 commercially approved CGTs.
- Raised full-year revenue guidance to $192 million - $196 million.
- Net loss attributable to common stockholders was $12.5 million, or $0.25 per share.